1. Scrip
  2. >>Therapy Areas
  3. >>Anti-infective

Naurex leads VC funding surge with $80 Series C

 
• By Mandy Jackson

December began with what looks like an end-of-year venture capital dealmaking rush, including an $80m Series C round to fund Naurex's drug candidates for depression and central nervous system (CNS) disorders plus four other sizeable US biotechnology deals.

December began with what looks like an end-of-year venture capital dealmaking rush, including an $80m Series C round to fund Naurex's drug candidates for depression and central nervous system (CNS) disorders plus four other sizeable US biotechnology deals.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anti-infective

GSK’s Blujepa Brings Innovation To The Antibiotic Space

 
• By Jessica Merrill

The US FDA approved Blujepa for the treatment of uncomplicated urinary tract infections, marking the first new mechanism of action for the infection in more than 30 years.

Profile: Anil Koul’s Journey From ‘Jumping Genes’ To Sirturo And AI-Led Drug Discovery

 
• By Anju Ghangurde

Professor Anil Koul shares vignettes of his life and career trajectory, a captivating mix of hope, science and destiny that took him to the lab of eminent cancer biologist Alex Ullrich at the Max Planck Institute and also saw him contribute to the development of breakthrough TB drug bedaquiline. He also talks about Medicine 3.0 and the intersection of science and spirituality.

Merck’s HIV Combo Shows Non-Inferiority To Gilead’s Biktarvy

 
• By Alaric DeArment

The company is developing doravirine and islatravir together as an alternative to therapies containing integrase inhibitors, like Biktarvy, especially as HIV patients age.

Gilead Pushes PrEP Envelope As ViiV Explores Self-Administered, Long-Acting Drugs

 
• By Alaric DeArment

The two companies were among those presenting data at CROI that highlighted the next frontiers of competition in the HIV space.

More from Therapy Areas